Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated November 1, 2024:
Effective December 1, 2024:
- Agamree, Emflaza
- Duvyzat
- Elagolix/Relugolix
- HCPA MS
- IL-5 Inhibitors
- Isturisa
- Kerendia
- Korlym
- Lupus
- Ohtuvayre
- Opzelura
- Otezla
- Piasky
- Primary Biliary Cholangitis (formerly Ocaliva)
- Recorlev
- Voxzogo
- Xphozah
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.
Institutional Providers
Professional Providers